Ogilvie A L, Antoni C, Dechant C, Manger B, Kalden J R, Schuler G, Lüftl M
Departments of Dermatology and Medicine III, University of Erlangen, Hartmannstr. 14, D-91052 Erlangen, Germany.
Br J Dermatol. 2001 Mar;144(3):587-9. doi: 10.1046/j.1365-2133.2001.04089.x.
In inflamed skin, keratinocytes and inflammatory cells both produce large amounts of tumour necrosis factor (TNF) -alpha, a cytokine with broad effects that are relevant to inflammation. Blockade of this proinflammatory cytokine by a monoclonal anti-TNF-alpha antibody might be effectively used in the treatment of inflammatory skin diseases.
To gather information about the efficacy of an anti-TNF-alpha antibody (infliximab) in the treatment of skin lesions of psoriatic arthritis.
Six patients with progressive joint disease and psoriatic skin lesions unresponsive to methotrexate therapy were treated with anti-TNF-alpha antibody. The Psoriasis Area and Severity Index was determined before and 10 weeks after initiation of therapy.
Improvement of psoriatic skin lesions was observed in all patients. In addition, a marked improvement of the joint disease was noted.
Therapy with anti-TNF-alpha antibody may be an effective treatment regimen for both psoriatic arthritis and psoriatic skin lesions.
在炎症性皮肤中，角质形成细胞和炎症细胞都会产生大量肿瘤坏死因子（TNF）-α，这是一种具有广泛作用且与炎症相关的细胞因子。单克隆抗TNF-α抗体阻断这种促炎细胞因子可能有效用于治疗炎症性皮肤病。
收集有关抗TNF-α抗体（英夫利昔单抗）治疗银屑病关节炎皮肤病变疗效的信息。
6例对甲氨蝶呤治疗无反应的进行性关节病和银屑病皮肤病变患者接受抗TNF-α抗体治疗。在治疗开始前和治疗10周后测定银屑病面积和严重程度指数。
所有患者的银屑病皮肤病变均有改善。此外，关节病也有明显改善。
抗TNF-α抗体治疗可能是银屑病关节炎和银屑病皮肤病变的有效治疗方案。
